In the midst of increasing global tensions, Chinese tech companies are recalibrating their international strategies, with many avoiding references to their origin. However, DP Technology, a startup founded in 2018, stands out by boldly embracing its Chinese roots. DP, short for "Deep Potential," is committed to applying artificial intelligence to molecular simulations, believing in the unifying power of "scientific research for humanity" to facilitate its global expansion.
Revolutionizing Scientific Computing
DP, advised by renowned mathematician Weinan E, offers a suite of tools for scientific computing. This process, integral to technology development and scientific research, involves computer simulations of mathematical models. Scientific computing finds applications in diverse fields such as biopharmaceutical research, car design, and semiconductor development.
While the tech world focuses on using AI for generating text, images, and videos, DP takes a distinctive path. The startup combines machine learning with molecular simulations, enhancing the speed and accuracy of solving real-world problems through virtual models.
"In the past, without a good computing or AI platform, everyone relied on experience-based trial and error. That process was often referred to as 'cooking' or 'alchemy,'" explains DP's CEO and founder, Sun Weijie.
Addressing Market Demands
Sun emphasizes the need for a breakthrough in research and development to meet growing consumer expectations for rapid technological advancements. DP responds to this demand by providing software and services tailored to industry players, offering a scientific computing platform and a SaaS platform for preclinical studies on drug discovery.
The startup's SaaS and service business models have garnered initial success in China, with contracts expected to reach nearly 100 million yuan ($14 million) in 2023. DP, positioning itself as the "poor kids" in comparison to industry giants like DeepMind, aims to take its strategies to Western markets.
Global Expansion Amid Challenges
DP, with around $140 million in funding, is preparing to enter the U.S. market. Despite potential challenges arising from the U.S.-China decoupling, DP remains confident in science's resilience. Sun believes that basic science and biopharmaceuticals, being shared by all of humanity, will withstand geopolitical complications.
As DP gears up for international expansion, the startup's unique approach to combining AI and molecular simulations positions it at the forefront of scientific advancements, aiming to make a global impact in the realm of technological innovation.
